Axsome drug succeeds in narcolepsy symptoms trial
Bio Pharma Dive
MARCH 25, 2024
One analyst argued that Axsome’s drug has “largely been falling under investor radars.” Despite the late-stage victory, shares of the New York-based biotech dipped more than 3%.
Let's personalize your content